Leede Jones Gab Weighs in on Sernova Corp.’s FY2024 Earnings (TSE:SVA)

Sernova Corp. (TSE:SVAGet Rating) – Investment analysts at Leede Jones Gab issued their FY2024 earnings estimates for Sernova in a report released on Tuesday, January 10th. Leede Jones Gab analyst D. Loe forecasts that the company will post earnings of ($0.02) per share for the year. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share. Leede Jones Gab also issued estimates for Sernova’s FY2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.09 EPS.

SVA has been the subject of a number of other reports. Roth Capital reiterated a “buy” rating on shares of Sernova in a report on Tuesday, September 20th. HC Wainwright reissued a “buy” rating and set a C$6.00 price objective on shares of Sernova in a research note on Tuesday.

Sernova Stock Performance

Shares of TSE SVA opened at C$1.06 on Friday. The company has a market cap of C$310.71 million and a PE ratio of -25.24. Sernova has a 12 month low of C$0.69 and a 12 month high of C$1.80. The company has a debt-to-equity ratio of 0.73, a current ratio of 18.26 and a quick ratio of 18.11. The company has a 50-day simple moving average of C$0.83 and a 200-day simple moving average of C$0.95.

About Sernova

(Get Rating)

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.

Featured Articles

Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.